Conference Presentations
PLENARY SESSIONS
-
THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM REGULATORY DECISIONS
Presentation
Shelby D. Reed
PhD, RPh, Professor, Duke University, Durham, USA
Matt Reaney
FRSPH, MSc, Global Head of Clinical Outcomes, Sanofi, Guildford, UK
Jeff Shuren
MD, JD, Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, USA
Bennett Levitan
MD, PhD, Senior Director, Benefit-risk Assessment, Janssen Research & Development, LLC, Epidemiology, Titusville, USA
ISSUE PANEL PRESENTATIONS
-
IP10 : PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?
Presentation
Cat Davis Ahmed
MBA, Vice President, Policy and Outreach, The FH Foundation, Pasadena, USA
-
IP10 : PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?
Presentation
Seth J. Baum
MD, President, American Society for Preventive Cardiology; Chief Medical Officer, Excel Medical Clinical Trials, Affiliate Professor of Medicine, Schmidt College of Medicine, Florida Atlantic University (FAU), Boca Raton, USA
-
IP11 : “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (Invited Issue Panel)
-
IP11 : “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (Invited Issue Panel)
Presentation
Stacie B. Dusetzina
PhD, Associate Professor, Health Policy, Vanderbilt University School of Medicine, Ingram Associate Professor of Cancer Research, Nashville, USA
-
IP13 : SURROGATE OUTCOMES IN ONCOLOGY: HOW CAN THEY BE USED TO PREDICT OVERALL SURVIVAL IN CLINICAL PRACTICE AND PAYER DECISION MAKING?
Presentation
Louis P. Garrison
PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, School of Pharmacy, Seattle, USA
-
IP16 : IN THE ELECTRONIC HEALTH RECORD ERA, DO WE STILL NEED CLINICAL REGISTRIES?
Presentation
Lisa M. Wruck
PhD, Director, Duke Clinical Research Institute, Center for Predictive Medicine, Durham, USA
Marc Berger
MD, Vice President, Pfizer, Inc., Real World Data and Analytic, New York, USA
Sharon Hensley Alford
PhD, Associate Chief Health Officer, IBM Watson Health, Cambridge, USA
Matthew T. Roe
MD, MHS, Professor of Medicine, Duke University, Duke Clinical Research Institute, Durham, USA
-
IP17 : HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?
Presentation
Katarzyna Kolasa
PhD, Senior Research Fellow, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
-
IP17 : HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?
Presentation
Cynthia Iglesias
PhD, Senior Research Fellow, University of York, Centre for Health Economics, York, UK
-
IP19 : VALUE ASSESSMENT FRAMEWORKS IN AN ERA OF PERSONALIZED MEDICINE: SHARED OBJECTIVES OR IRRECONCILABLE DIFFERENCES?
Presentation
Robert W Dubois
MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, USA
Kristen Migliaccio-Walle
BS, Director, Xcenda, LLC, Global Health Economics & Outcomes Research, Palm Harbor, USA
Daniel A Ollendorf
PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, USA
Sara Traigle van Geertruyden
JD, Executive Director, Partnership to Improve Patient Care, Washington, USA
-
IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION
-
IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION
Presentation
Ilene L. Hollin
PhD, MPH, Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics, Washington, USA
-
IP20 : THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION
Presentation
Mike Ciarametaro
MBA, Director of Research, National Pharmaceutical Council, Washington, USA
-
IP22 : CHALLENGES AND OPPORTUNITIES IN THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING FOR IN VITRO DIAGNOSTICS
Presentation
Tyler J. O'Neill
DVM, MSc, PhD, Scientist, Roche Diagnostics, Diagnostics Information Solutions, Pleasanton, USA
Asif Jan
PhD, Lead, Roche Diagnostics, Diagnostics Information Solutions, Pleasanton, USA
Brad Spring
BS, Vice President, BD Life Sciences, Regulatory Affairs, Sparks, USA
Michael S. Waters
PhD, SHIELD Team Lead; CDRH RWE Tactical Team – Diagnostics, Food and Drug Administration (FDA), Office of in vitro Diagnostics and Radiologic Health (OIR), Silver Spring, USA
-
IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!
Presentation
Helen Doll
PhD, Strategic Lead, Quantitative Science, Clinical Outcomes Solutions, Folkestone, UK
-
IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!
-
IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!
Presentation
Helen Kitchen
MSc, Senior Consultant, DRG Abacus, Clinical Outcomes Assessment, Manchester, UK
-
IP23 : ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!
Presentation
Kathryn Lasch
PhD, Executive Director, Patient Reported Outcomes, Pharmerit International, Newton, USA
-
IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED
Presentation
Renée J G Arnold
PharmD, Director, Navigant Consulting, Inc., Life Sciences, San Francisco, USA
-
IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED
-
IP9 : LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED
Presentation
Neil Hawkins
PhD, Professor of Health Technology Assessment (HTA), University of Glasgow, Health Economics & Health Technology Assessment, Glasgow, UK
WORKSHOP PRESENTATIONS
-
W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)
Presentation
Yiduo Zhang
PhD, Director, Health Economics and Payer Analytics, AstraZeneca, Global Payer Evidence and Pricing, Gaithersburg, USA
-
W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)
-
W1 : TIME TO LOOK BEYOND KAPLAN-MEIER CURVES? CHALLENGES AND OPPORTUNITIES IN OVERALL SURVIVAL EXTRAPOLATIONS FOR IMMUNO-ONCOLOGY TRIALS -- SCIENTIFIC RATIONALE FOR USING PATIENT-LEVEL BIOMEDICAL INFORMATION (Advanced Workshop)
Presentation
Scott D. Ramsey
MD, PhD, Director, Fred Hutchinson Cancer Research Center and University of Washington, Public Health Sciences, Seattle, USA
-
W10 : MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE
-
W10 : MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE
Presentation
Paul Melmeyer
MPP, Director of Federal Policy, National Organization for Rare Disorders (NORD), Washington, USA
-
W11 : CHOOSING THE APPROPRIATE MODELING METHOD: CAUSAL MODELING, HEALTH ECONOMIC MODELING, CONSTRAINED OPTIMIZATION OR SIMULATION?
Presentation
Kalyan S. Pasupathy
PhD, Faculty, Mayo Clinic, Healthcare Policy & Research, Rochester, USA
Deborah A Marshall
PhD, Professor, University of Calgary, Calgary, Canada
Praveen Thokala
PhD, Research Fellow, University of Sheffield, School of Health and Related Research, Sheffield, UK
William H Crown
PhD, Chief Scientific Officer, OptumLabs, Cambridge, USA
-
W12 : COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA (Advanced Workshop)
Presentation
Alisa Stephens-Shields
PhD, Assistant Professor, University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, USA
-
W12 : COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA (Advanced Workshop)
Presentation
Laura Hatfield
PhD, Associate Professor, Harvard Medical School, Department of Health Care Policy, Boston, USA
-
W2 : WHAT IS PATIENT EXPERIENCE DATA? THE REGULATORY PERSPECTIVE
Presentation
Megan Moncur
M.S, Scientist, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, USA
Martin Ho
U.S. Food and Drug Administration, Center for Devices and Radiological Health,
Pujita Vaidya
MPH, Director (Acting), Decision Support and Analysis Team, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Office of Strategic Programs/Office of Program and Strategic Analysis, Silver Spring, USA
Elektra Papadopoulos
MD, MPH, Associate Director, Clinical Outcome Assessments Staff, U.S. Food and Drug Administration, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Silver Spring, USA
-
W3 : DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE
Presentation
Murray Aitken
MBA, Executive Director, IQVIA Institute for Human Data Science, New York, USA
Karen Schoelles
MD, SM, Project Director, AHRQ Healthcare Horizon Scanning System and Director, ECRI Institute Evidence-based Practice Center, ECRI Institute, Technology Assessment, Plymouth Meeting, USA
Penny Mohr
MA, Senior Program Officer, Patient-Centered Outcomes Research Institute (PCORI), Improving Healthcare Systems, Washington, USA
Jasmine Bihm
DrPH, MPH, Staff Fellow, Agency for Healthcare Research and Quality (AHRQ), Center for Evidence and Practice Improvement, Rockville, USA
-
W3 : DIGITAL HEALTH: EVALUATING THE EVIDENCE, IDENTIFYING GAPS, PRODUCING BETTER SCIENCE
Presentation
Murray Aitken
MBA, Executive Director, IQVIA Institute for Human Data Science, New York, USA
Jasmine Bihm
DrPH, MPH, Staff Fellow, Agency for Healthcare Research and Quality (AHRQ), Center for Evidence and Practice Improvement, Rockville, USA
-
W4 : BIOSIMILARS, UTILIZATION, AND POST-MARKETING SURVEILLANCE IN THE UNITED STATES (Invited Workshop)
Presentation
Cate Lockhart
PharmD, PhD, Program Director, Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, USA
Mark J. Cziraky
PharmD, CLS, Vice President of Research, Healthcore, Wilmington, USA
Mike Blum
MD, MPH, Deputy Director, U.S. Food & Drug Administration, Office of Pharmacovigilance and Epidemiology, Silver Spring, USA
-
W6 : ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS
Presentation
Americo Cicchetti
DSc, Professor of Management and Healthcare Management & Director, Catholic University of Sacred Heart (ALTEMS), Graduate School of Health Economics and Management, Rome, Italy
-
W6 : ECONOMIC EVALUATION OF VACCINATION PROGRAMS: EXPLORING MULTIPLE METHODS
Presentation
David E Bloom
PhD, Clarence James Gamble Professor of Economics and Demography, Harvard University, TH Chan School of Public Health, Boston, USA
Josephine Mauskopf
PhD, Vice President, RTI Health Solutions, Health Economics, Research Triangle Park, USA
-
W7 : ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE: DOES THE HEALTH ECONOMIST NEED TO ADAPT TO THE MACHINE?
Presentation
Augustin Terlinden
Msc, Health Economist, Navigha, Health Economics, Tervuren, Belgium
Amine Aissaoui
PhD in Economics, PharmD, MSc, Researcher, Paris Dauphine University, PSL, LEDA-LEGOS, Paris, France
Olivier Ethgen
MSc, PhD, Adjunct Professor Health Economics, University of Liege, Liege, Belgium
Patricia A Deverka
MD, MS, MBE, Senior Researcher, American Institutes for Research, Chapel Hill, USA
-
W8 : ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS
Presentation
Elektra Papadopoulos
MD, MPH, Associate Director, Clinical Outcome Assessments Staff, U.S. Food and Drug Administration, Office of New Drugs, Center for Drug Evaluation and Research (CDER), Silver Spring, USA
-
W8 : ASSESSING PATIENT FUNCTIONING IN DRUG DEVELOPMENT USING PERFORMANCE OUTCOME ASSESSMENTS: EVIDENTIARY, METHODOLOGICAL, AND OPERATIONAL CONSIDERATIONS
Presentation
Heather Adams
PhD, Associate Professor, University of Rochester Medical Center, Department of Neurology & Pediatrics, Rochester, USA
-
W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)
Presentation
Kathryn O’Callaghan
PhD, Assistant Director of Strategic Programs, U.S. Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, USA
-
W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)
Presentation
Kevin Marsh
PhD, Director, Evidera, Modelling and Simulation and Senior Research Scientist, Health Economics, London, UK
-
W9 : NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA (Advanced Workshop)
Presentation
Jui-Chen Yang
MEM, Research Economist, Duke Clinical Research Institute, Preference Evaluation Research Group, Durham, USA
ISPOR FORUMS
-
F1 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING
Presentation
A. Simon Pickard
PhD, Professor, University of Illinois at Chicago, College of Pharmacy, Chicago, USA
Bruce Crawford
MA, MPH, Senior Principal, IMS Japan K.K., Real-World Evidence Solutions, Japan & APAC, Minato-ku, Tokyo, Japan
John E. Brazier
PhD, Professor, University of Sheffield, Health Economics, School of Health and Related Research, Sheffield, UK
-
F2 : HANDLING MISSING VALUES IN REAL-WORLD DATA: ARE THERE CHALLENGES FOR REGULATORY DECISIONS FOR MEDICAL PRODUCTS?
Presentation
Judith J. Stephenson
SB, SM, Principal Scientist, Survey Research, HealthCore, Inc., Wilmington, USA
Nneka C. Onwudiwe
PhD, PharmD, MBA, PRO/PE Regulatory Reviewer, U.S. Food and Drug Administration, Office of Prescription Drug Promotion, CDER, Silver Spring, USA
Samuel Wilson
PhD, BS, MS, Associate Director-Statistics, Astellas Pharmaceuticals US, Inc., Northbrook, USA
Helene Karcher
X-Eng, MIT PhD, Managing Vice-President, Global Head, Real World Modeling, LASER Analytica, London, UK
Laurence Djatche
PharmD, Health Economics and Outcomes Research Post-Doctoral Fellow, Thomas Jefferson University, College of Population Health, Philadelphia, USA
-
F3 : DEFINING PATIENT CENTEREDNESS AND ENGAGEMENT IN HEOR: PROPOSED DEFINITION AND STAKEHOLDER RESPONSE
Presentation
Rachel L. Harrington
BA, Pre-Doctoral Fellow, University of Illinois at Chicago, Institute for Health Research and Policy/College of Pharmacy, Chicago, USA
Suzanne Schrandt
JD, Director, Patient Engagement, Arthritis Foundation, Atlanta, USA
Eleanor M. Perfetto
PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland, National Health Council, and Senior Vice President, Strategic Initiatives, Washington, USA
Sarah Donelson
MA, Lead, Patient-Centered Research, Genentech, San Francisco, USA
-
F4 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR
Presentation
Laura T. Pizzi
PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
Bill Marder
PhD, MA, BA, Chief Data Strategist, IBM Watson Health, Cambridge, USA
-
F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
Presentation
Sang-Soo Lee
MBA, Director, Corporate Affairs, Medtronic Korea, Co., Ltd., Seoul, South Korea
-
F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
-
F5 : ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK
-
F6 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS
Presentation
Rachael Fleurence
PhD, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, USA
Anirban Basu
PhD, Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, USA
James F. Murray
PhD, Research Fellow, Eli Lilly and Company, Global Health Outcomes - COE, Carmel, USA
Lotte Steuten
PhD, Member, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, USA
Gillian D Sanders Schmidler
PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, Duke University, The Robert J. Margolis, MD, Center for Health Policy, Washington, USA
-
F7 : ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN
Presentation
Richard J. Willke
PhD, Vice President, Outcomes & Evidence Lead CV/Metabolic, Pfizer Inc., Pain, Urology, Gender Health, Global Health & Value, New York, USA
Laura T. Pizzi
PharmD, MPH, Professor and Director, Rutgers University, Center for Health Outcomes Policy and Economics, Piscataway, USA
Brian Ung
PharmD, MS, Post-Doctoral Fellow, Celgene Corporation, US Health Economics and Outcomes Research, Summit, USA
Jason Harris
BA, Associate Director of Policy and Programs, National Health Council, Washington, USA
-
F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Presentation
Makoto Kobayashi
PhD, M.Eng., Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan
-
F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Presentation
Sukyeong Kim
PHD, Director, National Evidence-Based Healthcare Collaborating Agency, Coordinating Center for National Health Clinical Research, Seoul, Korea, Republic of (South)
-
F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Presentation
Jitendar Sharma
PhD, Head-Division of Healthcare Technology, Ministry of Health & Family Welfare, National Health Systems Resource Center, New Delhi, India
-
F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Presentation
Jianwei Xuan
MD, PhD, Advisory Professor, Fudan University, School of Public Health, Shanghai, China
-
F8 : REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Presentation
Bor-Sheng Ko
MD, PhD, Attending Physician and Clinical Assistant Professor, National Taiwan University Hospital, BMT Unit and Hematology Division, Department of Internal Medicine, Taipei, Taiwan
-
F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS
Presentation
Ramiro E. Gilardino
MD, MSc, Director, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Global Networks Latin America, Lawrenceville, USA
-
F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS
-
F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS
Presentation
Louis Garrison
PhD, 2015-2016 ISPOR President-elect, Board of Directors and Professor, University of Washington, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, Seattle, USA
-
F9 : NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS